Evidence map›Paper›PMID 36067236›Full record

ArticlePLoS pathogens2022

Elucidation of TRIM25 ubiquitination targets involved in diverse cellular and antiviral processes.

Emily Yang, Serina Huang, Yasaman Jami-Alahmadi, Gerald M McInerney, James A Wohlschlegel, Melody M H Li

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 40 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Emily YangMolecular Biology Institute, University of California, Los Angeles, California, United States of America.
Serina HuangDepartment of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Yasaman Jami-AlahmadiDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Gerald M McInerneyDepartment of Microbiology, Tumor, and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
James A WohlschlegelDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, California, United States of America.
Melody M H LiMolecular Biology Institute, University of California, Los Angeles, California, United States of America.ORCID 0000-0002-6905-7940
University of California, Los Angeles · USKarolinska Institutet · SE

Funding

MULTIDISCIPLINARY TRAINING IN MICROBIAL PATHOGENESIST32AI007323 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Peter John Bradley · 1988 to 2026
$8.6M
Proteolytic Control of Iron Metabolism by the Ubiquitin Ligase FBXL5R01GM089778 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WOHLSCHLEGEL, JAMES AKIRA · 2010 to 2023
$4.0M
Functional analysis of host and viral determinants for ZAP inhibitionR01AI158704 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LI, MELODY · 2021 to 2025
$1.9M
NIAID NIH HHS R01 AI158704NIAID NIH HHS T32 AI007323NIGMS NIH HHS R01 GM089778
6 · The paper itself

Abstract

The tripartite motif (TRIM) family of E3 ubiquitin ligases is well known for its roles in antiviral restriction and innate immunity regulation, in addition to many other cellular pathways. In particular, TRIM25-mediated ubiquitination affects both carcinogenesis and antiviral response. While individual substrates have been identified for TRIM25, it remains unclear how it regulates diverse processes. Here we characterized a mutation, R54P, critical for TRIM25 catalytic activity, which we successfully utilized to "trap" substrates. We demonstrated that TRIM25 targets proteins implicated in stress granule formation (G3BP1/2), nonsense-mediated mRNA decay (UPF1), nucleoside synthesis (NME1), and mRNA translation and stability (PABPC4). The R54P mutation abolishes TRIM25 inhibition of alphaviruses independently of the host interferon response, suggesting that this antiviral effect is a direct consequence of ubiquitination. Consistent with that, we observed diminished antiviral activity upon knockdown of several TRIM25-R54P specific interactors including NME1 and PABPC4. Our findings highlight that multiple substrates mediate the cellular and antiviral activities of TRIM25, illustrating the multi-faceted role of this ubiquitination network in modulating diverse biological processes.

Indexed as

Antiviral AgentsDNA HelicasesInterferonsNucleosidesPoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinsTripartite Motif ProteinsUbiquitinationUbiquitin-Protein LigasesUbiquitinsAntiviral AgentsDNA HelicasesInterferonsNucleosidesPoly-ADP-Ribose Binding ProteinsRNA HelicasesRNA Recognition Motif ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesUbiquitins

Identifiers

PMID36067236
PMCPMC9481182
OpenAlexW4294844745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.